Bal Pharma Limited (NSE:BALPHARMA)

Market Cap	1.32B
Revenue (ttm)	2.95B
Net Income (ttm)	71.57M
Shares Out	n/a
EPS (ttm)	4.58
PE Ratio	18.44
Forward PE	n/a
Dividend	1.20 (1.46%)
Ex-Dividend Date	Sep 18, 2025

Volume	8,103
Average Volume	20,288
Open	83.24
Previous Close	81.92
Day's Range	81.55 - 83.24
52-Week Range	78.06 - 140.95
Beta	0.18
RSI	45.66
Earnings Date	Aug 8, 2025

About Bal Pharma

Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic p...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1987
• Employees: 986
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: BALPHARMA

Financial Performance

In 2024, Bal Pharma's revenue was 3.03 billion, a decrease of -10.65% compared to the previous year's 3.39 billion. Earnings were 72.15 million, a decrease of -2.39%.